Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy.
Diabetic vascular complication is a leading cause of acquired blindness, end-stage renal failure, a variety of neuropathies and accelerated atherosclerosis, which could account for disabilities and high mortality rates in patients with diabetes. Chronic hyperglycemia is essentially involved in the pathogenesis of diabetic micro- and macrovascular complications via various metabolic derangements. In this review, we discuss the molecular mechanisms of diabetic retinopathy and nephropathy, especially focusing on advanced glycation end products (AGEs) and their receptor (RAGE) system. Several types of AGE inhibitors and their therapeutic implications in diseases, including diabetic microangiopathy, will be discussed in the next review article.
Yamagishi
S
S
Department of Internal Medicine III, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan. shoichi@med.kurume-u.ac.jp
Takeuchi
M
M
Inagaki
Y
Y
Nakamura
K
K
Imaizumi
T
T
D000818:Animals; D003925:Diabetic Angiopathies / Q000209:etiology* / Q000503:physiopathology; D003928:Diabetic Nephropathies / Q000209:etiology* / Q000503:physiopathology; D003930:Diabetic Retinopathy / Q000209:etiology* / Q000503:physiopathology; D017127:Glycation End Products, Advanced / Q000009:adverse effects* / Q000378:metabolism; D006801:Humans
D017127:Glycation End Products, Advanced